Investor Relations

Company Overview

Nivalis Therapeutics is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The Company’s lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease causing mutation in CF.

Investor Presentation
Download
  • 1
    Aug
  • Nivalis Therapeutics Reports Second Quarter 2016 Financial Results

    Cavosonstat achieves significant phase 2 enrollment milestones during quarter BOULDER, Colo., Aug. 01, 2016 (GLOBE…

Stock Information

NASDAQ:

NVLS

Price

Loading...

Change

Loading...

MKT Cap

Loading...

Volume

Loading...

52 week Low/High

Loading...

Day Low/High

Loading...

Latest Financial Results

Contact Information

Investor Relations
John Graziano
T: 646-378-2942
jgraziano@troutgroup.com

Transfer Agent
American Stock Transfer & Trust
6201 15th Avenue
Brooklyn, NY 11219

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.